Normal LH/FSH + Normal Total Testosterone + Low Free Testosterone

Pathophysiology

• 2-4% free (unbound, immediately bioavailable)
• 44-65% SHBG-bound (tightly bound, biologically inactive)
• 33-50% albumin-bound (weakly bound; dissociates readily - considered "bioavailable")

Causes of Elevated SHBG Leading to This Pattern

How to Proceed: Diagnostic Workup

• Measure free testosterone by equilibrium dialysis (gold standard) - direct immunoassay methods are unreliable.
• Alternatively, calculate free testosterone from total testosterone + SHBG + albumin using the Vermeulen equation.
• Free testosterone <225 pmol/L is associated with hypogonadism per EAU 2024 guidance.

• Will typically be elevated, explaining the discordance between total and free testosterone.

• Thyroid function tests (TSH, T3/T4) - rule out hyperthyroidism
• Liver function tests + hepatitis screen
• Review medications (anticonvulsants, exogenous estrogens)
• Consider age-related late-onset hypogonadism (LOH) if >40 years old

• Endocrine Society guidelines recommend diagnosing testosterone deficiency only when biochemical findings are accompanied by symptoms. If the patient is symptomatic + low free T, treatment is warranted even if total T is normal.

Symptoms of Low Free Testosterone (androgen deficiency)

Sexual/Reproductive

• Decreased libido (most specific symptom)
• Erectile dysfunction / reduced erectile quality
• Oligospermia or azoospermia
• Testicular atrophy (variable)

Metabolic/Musculoskeletal

• Decreased muscle mass and strength
• Increased fat mass (especially central/visceral)
• Decreased bone mineral density → risk of osteopenia/osteoporosis
• Reduced exercise tolerance

Neuropsychiatric

• Fatigue and low energy
• Depressed mood, irritability
• Poor concentration and cognitive performance
• Reduced motivation and "enjoyment of life"

Other

• Anemia (normocytic)
• Sleep disturbances
• Hot flashes (less common in men than women)
• Gynecomastia (especially if estrogen:androgen ratio is elevated)

Treatment Modalities

1. Treat the Underlying Cause (First Priority)

• Correct hyperthyroidism - normalizing thyroid function can reduce SHBG and restore free testosterone
• Manage liver disease
• Substitute/discontinue SHBG-elevating medications if possible
• Weight loss (if applicable) - while obesity lowers SHBG, achieving ideal weight generally improves the androgen milieu

2. Lifestyle Modification

• Weight reduction and resistance exercise
• Adequate sleep (testosterone and SHBG have diurnal variation)
• Alcohol limitation (alcohol promotes SHBG)
• Stress reduction

3. Testosterone Replacement Therapy (TRT)

4. SERMs (Selective Estrogen Receptor Modulators)

• Clomiphene citrate (off-label) - blocks estrogen negative feedback at the hypothalamus, increases LH/FSH and endogenous testosterone production.
• Useful in men who wish to preserve fertility, as TRT suppresses spermatogenesis.
• Not licensed for testosterone deficiency in most countries.

5. Aromatase Inhibitors

• Anastrozole, letrozole (off-label) - reduce peripheral conversion of testosterone to estradiol.
• Can modestly raise free testosterone by reducing estrogen-mediated SHBG upregulation.
• Limited evidence; not first-line.

Monitoring on TRT

• Serum testosterone (free + total): 3-6 months after initiation, then annually. Target mid-normal range.
• PSA + digital rectal examination: before starting, at 3-6 months, then annually.
• Hematocrit/hemoglobin: elevated erythropoiesis is the most common dose-dependent side effect. Hold if hematocrit >54%.
• Bone mineral density: DEXA at baseline if osteopenia suspected; recheck in 1-2 years.
• Liver function (if using oral agents).
• Lipid panel and cardiovascular risk assessment.

Contraindications to TRT

• Known or suspected prostate cancer
• Breast cancer in men
• Polycythemia (Hct >54%)
• Untreated obstructive sleep apnea
• Severe lower urinary tract symptoms (IPSS >19)
• Desire for fertility in the near term
• Recent MI or stroke (<6 months)
• Uncontrolled heart failure
• Thrombophilia

Summary Algorithm

Normal LH/FSH + Normal Total T + Low Free T
              ↓
Measure SHBG → likely ELEVATED
              ↓
Identify cause: age / hyperthyroidism / liver disease / medications
              ↓
Assess symptoms (libido, energy, mood, muscle mass, ED, bone density)
              ↓
      Symptomatic?
      ├─ YES → Treat underlying cause + lifestyle modification first
      │         → If insufficient: TRT (gel/patch/injection based on preference)
      └─ NO  → Monitor annually; no pharmacologic treatment needed

Recent evidence note: A 2024 review (PMID 39445719, Curr Opin Endocrinol Diabetes Obes) highlights that calculated free testosterone has both advantages and limitations and should be interpreted alongside clinical context, not used as the sole treatment trigger.

Mesterolone 25 mg + Clomiphene Citrate 25 mg in a Normal (Eugonadal) Male

Drug Profiles

Mesterolone (Proviron) - 25 mg

• Oral bioavailability: ~3% (very low due to extensive first-pass metabolism)
• Half-life: 12-13 hours
• Protein binding: ~98% (40% albumin, 58% SHBG - very high SHBG affinity, ~440% that of DHT in some studies)
• Metabolism: hepatic
• Excretion: urine

Clomiphene Citrate (CC) - 25 mg

• It is a racemic mixture of enclomiphene (trans-isomer, pure ER antagonist) and zuclomiphene (cis-isomer, weak ER agonist)
• Half-life: several days to weeks (zuclomiphene accumulates)
• 25 mg/day is a low therapeutic dose (approved range in males is 12.5-50 mg/day)

Combined Effects in a NORMAL (Eugonadal) Male

1. Hormonal Effects

• Blocks hypothalamic/pituitary estrogen receptors → removes negative feedback → LH and FSH rise above normal range (supraphysiologic gonadotropins)
• Leydig cells are over-stimulated → total testosterone rises above normal (can increase by 50-150% above baseline)
• Estradiol also rises in parallel (more substrate for aromatase from elevated testosterone)

• Mesterolone binds SHBG with very high affinity, occupying binding sites
• Endogenous testosterone is displaced from SHBG → free testosterone rises further (additive to CC's effect on total T)
• The combined result: markedly elevated free and total testosterone

• LH: elevated (CC effect)
• FSH: elevated (CC effect)
• Total testosterone: significantly elevated
• Free testosterone: markedly elevated (CC + mesterolone SHBG displacement)
• Estradiol: elevated (from excess testosterone aromatization driven by CC)
• SHBG: occupied/partially displaced by mesterolone

In a eugonadal male, this combination can drive testosterone to supraphysiologic levels. This is NOT a therapeutic use - it is more consistent with performance enhancement or recreational misuse.

2. Effects on Spermatogenesis

• Clomiphene: Increases FSH → may improve spermatogenesis; does not suppress HPG axis; considered fertility-preserving
• Mesterolone at 25 mg: At low therapeutic doses, mesterolone has minimal to no suppression of gonadotropins and has historically been used for oligospermia. It supports the androgen-dependent phases of spermatogenesis
• However: If the combination raises total testosterone significantly above normal (via CC), the resulting high testosterone → high estradiol → potential for estrogen breakthrough despite CC blockade → complex feedback disruption
• The elevated testosterone itself can begin to exert androgenic negative feedback at the pituitary (testosterone is also a direct negative feedback signal, independent of aromatization to estrogen)
• Net sperm effect: variable and unpredictable - modest short-term improvement possible, but supraphysiologic T can paradoxically impair spermatogenesis if levels overshoot

3. Clinical Effects in a Normal Male While ON the Drugs

• Increased libido and sexual drive (elevated free testosterone + DHT-like androgenic activity of mesterolone)
• Potentially improved mood and motivation (androgen effects on CNS)
• Modest increase in muscle hardness/tone (mesterolone is weak anabolic; testosterone rise adds more)
• Increased energy
• No water retention (mesterolone is non-aromatizable; though CC raises estrogen which may cause mild water retention)
• No gynecomastia from mesterolone itself, but CC's elevated estradiol can potentially cause gynecomastia or breast tenderness in some men

• Acne and oily skin (androgenic stimulation)
• Scalp hair thinning in genetically predisposed men (DHT-like activity of mesterolone)
• Mood changes: irritability, aggression, or mood swings (supraphysiologic androgen)
• Hot flashes (paradoxically, from CC's estrogen-receptor blockade at the thermoregulatory center)
• Headache, dizziness, visual disturbances (CC-related)
• Elevated hematocrit (polycythemia risk, mainly from testosterone rise driven by CC)
• Elevated PSA (androgenic stimulation of prostate)
• Testicular volume maintained or slightly increased (CC increases gonadotropins, so testes are stimulated)

Effects Once the Drugs Are STOPPED

• Short-term use (weeks)
• Long-term use (months)

For the Combination at These Low Doses (Short-term use, weeks to a few months)

• Half-life ~12-13 hours → cleared within 2-3 days
• Because it caused minimal HPG axis suppression at this dose (it doesn't aromatize, so lacks estrogen-mediated suppression; androgenic suppression at 25 mg is weak), the HPG axis was not significantly shut down
• Free testosterone rapidly returns to baseline as SHBG binding sites are vacated
• Recovery is rapid - typically within days to 1-2 weeks

• Enclomiphene half-life: ~hours to days; zuclomiphene: very long half-life, accumulates - can persist for weeks
• While CC is present, it was holding LH/FSH elevated artificially; once CC clears, the hypothalamus/pituitary "sees" elevated testosterone and estradiol (the overshoot built during CC therapy)
• The elevated estradiol (produced during CC-driven testosterone excess) will now reinstate negative feedback without CC blocking it
• Consequence: transient drop in LH, FSH, and testosterone - a short "crash" phase

Days 1-3:
- Mesterolone clears; free T begins to normalize
- CC gradually clears (enclomiphene faster, zuclomiphene slower)

Days 3-14 ("crash phase"):
- As CC clears, elevated estradiol from the cycle exerts full negative feedback
- LH and FSH may transiently drop below baseline
- Total and free testosterone can fall below normal baseline (temporary hypogonadal state)
- Symptoms: low libido, reduced energy, mood dip, possible mild depression

Weeks 2-6 ("recovery phase"):
- The HPG axis re-establishes its own setpoint
- For a eugonadal male who was NOT suppressed long-term, recovery is generally complete
- LH/FSH normalize → testosterone normalizes
- Most men recover fully to their pre-cycle baseline within 4-8 weeks

If Used Long-Term (Months)

• Prolonged supraphysiologic testosterone (via CC in a normal male) can cause the HPG axis setpoint to shift
• The HPT axis may take 3-6 months or longer to fully normalize
• In a small percentage of men, especially with extended use, there is risk of persistent suppression requiring medical intervention (clomiphene, hCG, or specialist referral)

Summary of On-Drug vs. Off-Drug Effects

Important Clinical Points

1. This combination is not a recognized therapeutic protocol for a eugonadal male. In normal men, it creates an artificial supraphysiologic androgen state.
2. Mesterolone at 25 mg is considered a very low dose - in clinical use it is typically given at 75-150 mg/day. At 25 mg, its direct androgenic effects are modest; its main action at this dose is SHBG displacement.
3. Clomiphene is only FDA-approved in women. Its use in men is off-label and, per Endocrine Society guidelines, is only appropriate for symptomatic hypogonadal men (not normal men).
4. Recovery in a healthy eugonadal male after short-term use at these doses is expected to be complete - the HPG axis was not deeply suppressed because mesterolone barely suppresses it and CC was actually keeping LH/FSH elevated rather than suppressing them.
5. The "crash" after stopping CC is a well-recognized phenomenon and is exactly why clomiphene is used to restart the HPG axis in men after anabolic steroid withdrawal - because it stimulates the axis. When you stop it, you briefly lose that stimulation, and the residual estradiol creates a temporary dip.

References: Harrison's Principles of Internal Medicine 22E; Campbell Walsh Wein Urology; Smith & Tanagho's General Urology 19th Ed.; Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Tietz Textbook of Laboratory Medicine 7th Ed.; WHO/INCHEM Mesterolone Monograph (PIM 904); Varma TR et al., Int J Gynaecol Obstet 1988 (PMID 2892728)

Mesterolone (Proviron) in a Normal Male - Complete Dose-by-Dose Analysis

Pharmacological Recap (Brief)

The Key Paradox: Does Mesterolone Suppress the HPG Axis?

Why mesterolone was traditionally thought to be "non-suppressive":

1. It cannot aromatize to estrogen - so it lacks the estrogen-mediated component of negative HPG feedback
2. At low therapeutic doses (25-50 mg), early studies showed minimal LH/FSH suppression
3. It does not reduce spermatogenesis at low doses

Why suppression still occurs at higher doses:

1. Testosterone (and androgens generally) suppress the hypothalamic GnRH pulse generator via direct androgenic negative feedback, independent of estrogen conversion
2. Exogenous mesterolone suppresses endogenous testosterone production by this mechanism at higher doses
3. Wang et al. (1974) - the only published study specifically on normal men - found measurable effects on LH, FSH, and testosterone at therapeutic doses (PMID: 4418512, Andrologia)
4. Jackaman et al. (1977) - in oligospermic men treated for 6-9 months, found significant decrease in serum testosterone (17.05 → 14.7 nmol/L, p<0.01) and a paradoxical increase in LH - suggesting the HPG axis was responding to reduced intratesticular testosterone (PMID: 872444, Clin Endocrinol)
5. HealthRX clinical review noted: "exogenous androgens, including non-aromatizable ones, suppress LH and FSH secretion in a dose-dependent manner... men taking mesterolone without concurrent testosterone replacement may develop lower testosterone levels than they started with"

Dose-Specific Effects in a Normal Male

25 mg/day (1 tablet once daily)

• Libido support as an adjunct (e.g., alongside TRT to maintain free T)
• Leydig cell insufficiency post-puberty (Bayer PIL: "1 tablet twice daily for several months")
• Historically: mild androgen deficiency symptoms

• Occupies SHBG binding sites → free testosterone rises modestly (endogenous T is displaced)
• Provides weak direct androgenic stimulation (AR agonism)
• LH/FSH: minimally affected at this dose; studies show no significant suppression at 25 mg
• Endogenous total testosterone: may decrease slightly (by ~10-15%) due to mild androgenic feedback, but remains within normal range
• Spermatogenesis: largely preserved; no clinically significant impairment at this dose

• Very modest androgenic effects (libido increase, mild oiliness)
• Minimal HPG suppression; endogenous T essentially maintained
• Scalp hair in genetically predisposed individuals: mild acceleration of DHT-pattern loss possible
• 25 mg is genuinely a sub-therapeutic dose for most indications - it is actually the lowest unit of commercially available tablets (Proviron 25 mg = 1 tablet), and most clinical protocols start at 50-75 mg/day

• No formally defined limit at this dose in clinical literature
• Bayer PIL recommends "continuous treatment for several months" for androgen deficiency
• For fertility enhancement: ~90 days (one full spermatogenic cycle)

50 mg/day (2 × 25 mg)

• Mild androgen deficiency / late-onset hypogonadism (maintenance dose)
• Bayer PIL: "1 tablet of Proviron twice a day" for maintenance of androgen deficiency disorders
• Used in some European centers as a first-line androgen for symptomatic older men with low-normal testosterone

• Free testosterone: notable increase (SHBG saturation effect is stronger; more binding sites occupied)
• LH: borderline/mild suppression begins
• Endogenous total testosterone: suppression of ~15-25% may occur with prolonged use
• Sperm: minimal impact at this dose; most studies show preserved spermatogenesis
• Androgenic effects more noticeable: increased libido, increased body hair, acne possible
• HDL cholesterol: may begin to show mild reduction (class effect of androgens on lipids)

• Begins to suppress endogenous testosterone production meaningfully if used for months
• Acne, increased oiliness of skin
• Scalp hair loss acceleration in androgenetically susceptible men
• Increased erection frequency (priapism risk if persistent)
• Mild prostate stimulation (PSA may rise mildly)
• Cardiovascular: mild adverse lipid effects (HDL reduction, LDL increase) - class effect

• Clinical protocols typically limit to 3-6 months then reassess
• Bayer PIL recommends "several months" of continuous therapy

75 mg/day (3 × 25 mg)

• Male infertility due to oligospermia (one of the historical indications)
• Bayer PIL: "1 tablet 2-3 times per day" for infertility
• Androgen deficiency with more severe symptoms requiring faster androgenic effect

• Free testosterone significantly elevated (SHBG near-saturation; large displacement of endogenous T from binding)
• LH suppression becomes apparent: direct androgenic feedback begins to meaningfully suppress GnRH pulsatility
• Endogenous total testosterone: may drop 20-30% below the individual's own baseline
• Sperm: variable - the increased free intratesticular androgens may initially maintain spermatogenesis, but LH suppression over months begins to reduce intratesticular T and impair sperm production
• More pronounced androgenic side effects

• All issues from lower doses, more pronounced
• More consistent LH/FSH suppression with prolonged use
• Cardiovascular risk more relevant: HDL may drop by 10-20%, LDL rises
• Prostate: DHT-like activity directly stimulates prostate tissue; BPH risk in predisposed men
• Polycythemia: mild rise in hematocrit possible (androgenic erythropoiesis stimulation)

• Clinical studies used this range for up to 12 months for infertility
• Generally limited to 3-6 months before hormonal assessment and adjustment

100 mg/day (4 × 25 mg)

• Primary indication for male infertility/oligospermia in historical European practice
• Wang et al. (1983) RCT: used 100 mg/day for 6 months in idiopathic oligospermia - found NO significant increase in mean sperm concentration or pregnancy rate vs. placebo (PMID: 6411497, Fertil Steril)
• Varma & Patel (1988): used 100-150 mg/day for 12 months in 250 subfertile men with oligospermia; found significant improvement in sperm density and motility in moderately oligospermic men (5-20 million/mL); 46% pregnancy rate; no depressing effect on normal or low FSH/LH; depressed elevated FSH/LH in only 25% of patients with elevated levels (PMID: 2892728, Int J Gynaecol Obstet)
• Jackaman et al. (1977): significant fall in serum testosterone at doses used for 6-9 months (PMID: 872444)

• Meaningful HPG suppression: LH and FSH show measurable decline with prolonged use
• Endogenous testosterone: may fall 25-35% below baseline
• SHBG near-saturated; significant free testosterone from SHBG displacement
• Net androgenic exposure: substantially supraphysiologic (mesterolone + displaced free T together)
• Semen quality: paradoxically worsened possible in a normal male (who already has normal baseline) if HPG suppression becomes significant

• All prior issues more pronounced
• Real risk of secondary hypogonadism pattern: LH falls, Leydig cells understimulated, endogenous T production drops - but total DHT-like androgenic activity remains high due to mesterolone itself
• Lipid profile: significant HDL reduction
• Prostate stimulation: DHT has more potent prostate effects than testosterone; DHT is the primary intraprostatic androgen. Mesterolone, being a DHT analogue, directly stimulates prostatic androgen receptors. PSA may rise; BPH possible with long-term use in predisposed men
• Cardiovascular risk: cardiovascular adverse events comparable to other oral AAS per Wikipedia pharmacology data

• Clinical infertility studies: up to 12 months (one spermatogenic cycle = 90 days minimum; some studies ran 12 months)
• Bayer PIL: "approximately 90 days" for infertility indication; repeat after interval of several weeks if needed
• For normal men, 100 mg/day has no supported therapeutic duration - this is already off-label use

150 mg/day (6 × 25 mg) - "High Dose"

• Used in the Gerris et al. (1991) multicenter double-blind RCT for idiopathic male infertility
• 52 patients, 12 months treatment, 150 mg/day vs. placebo
• Result: pregnancy rate was LOWER in the mesterolone group (26%) than placebo (48%); while motility and morphology improved, the overall fertility outcome was worse
• This study effectively discredited high-dose mesterolone for male infertility (PMID: 1900485, Fertil Steril)

• Significant HPG axis suppression
• Endogenous testosterone production suppressed 30-40%+ below baseline
• Paradoxically, total androgenic load is very high, but endogenous testicular testosterone is reduced
• Intratesticular testosterone (which drives spermatogenesis) depends on LH-stimulated Leydig cell production - and this is impaired at this dose
• This explains the Gerris RCT result: mesterolone improved peripheral sperm parameters superficially but impaired spermatogenesis more fundamentally

• Clinically meaningful HPG suppression
• Reduced intratesticular testosterone → impaired spermatogenesis
• Significant adverse lipid effects
• Elevated hematocrit/polycythemia risk
• Prostate stimulation
• Psychological: irritability, mood swings
• In the Gerris RCT, semen improvement did not translate to better pregnancy outcomes

• Not recommended beyond 12 months even in the clinical trial setting
• In normal men: no supported therapeutic duration exists; this dose has no indication in eugonadal males

>150 mg/day (Performance/Misuse Range)

Consolidated Dose-by-Dose Reference Table

Specific Concerns for a Normal Eugonadal Male (Any Dose)

1. Paradox of Endogenous Testosterone Reduction

2. No Gynecomastia from Mesterolone Itself

3. No Hepatotoxicity

4. Prostate: Lower Risk Than Expected

5. Cardiovascular Risk

6. Scalp Hair Loss

7. Fertility in a Normal Male

Key Studies Summary

Bottom Line for a Normal Male

References: Campbell Walsh Wein Urology; Bayer Proviron PIL Nov 2023; Wang et al. 1974 (PMID 4418512); Jackaman et al. 1977 (PMID 872444); Wang et al. 1983 (PMID 6411497); Varma & Patel 1988 (PMID 2892728); Gerris et al. 1991 (PMID 1900485); Wikipedia/Mesterolone pharmacology; WHO/INCHEM PIM 904